United Therapeutics Co. (NASDAQ:UTHR – Get Free Report) EVP Paul A. Mahon sold 6,000 shares of the firm’s stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $225.76, for a total transaction of $1,354,560.00. Following the completion of the transaction, the executive vice president now directly owns 36,599 shares of the company’s stock, valued at $8,262,590.24. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
United Therapeutics Price Performance
Shares of NASDAQ:UTHR opened at $224.43 on Friday. The stock has a market cap of $10.53 billion, a PE ratio of 12.37 and a beta of 0.57. The company’s fifty day moving average is $225.99 and its 200 day moving average is $225.92. United Therapeutics Co. has a 52 week low of $204.44 and a 52 week high of $283.09. The company has a quick ratio of 8.40, a current ratio of 4.65 and a debt-to-equity ratio of 0.09.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last issued its earnings results on Wednesday, November 1st. The biotechnology company reported $5.38 EPS for the quarter, topping analysts’ consensus estimates of $5.10 by $0.28. The company had revenue of $609.40 million for the quarter, compared to analysts’ expectations of $585.82 million. United Therapeutics had a net margin of 40.82% and a return on equity of 17.10%. The firm’s revenue was up 18.1% compared to the same quarter last year. During the same quarter last year, the company earned $4.91 EPS. Research analysts anticipate that United Therapeutics Co. will post 19.03 earnings per share for the current year.
Hedge Funds Weigh In On United Therapeutics
Analyst Ratings Changes
UTHR has been the subject of several analyst reports. StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday. JPMorgan Chase & Co. lifted their price objective on shares of United Therapeutics from $290.00 to $294.00 and gave the stock an “overweight” rating in a report on Thursday. HC Wainwright reaffirmed a “buy” rating and set a $300.00 price objective on shares of United Therapeutics in a report on Thursday, August 3rd. Morgan Stanley dropped their price objective on shares of United Therapeutics from $318.00 to $314.00 and set an “overweight” rating for the company in a report on Thursday. Finally, Wedbush reaffirmed an “outperform” rating and set a $308.00 price objective (up from $307.00) on shares of United Therapeutics in a report on Thursday. One analyst has rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $288.00.
About United Therapeutics
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
- Five stocks we like better than United Therapeutics
- Earnings Per Share Calculator: How to Calculate EPS
- MarketBeat Week in Review – 10/30 – 11/3
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Shocking uranium play that hedge funds kept hidden
- Mega Cap Stocks: What They Are and How to Invest
- Dependable dividends: Why utility stocks are on fire
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.